Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDRiver Solid Tumors 320
NCT05396833Phase 1Completed
- Sponsor
- EMD Serono
- Start
- Jun 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of tuvusertib in solid tumor, triple negative breast cancer (TNBC), Epithelial Ovarian Cancer (EOC) and 4 more (7 arms), sponsored by EMD Serono. Primary endpoints: Dose-Limiting Toxicities, Adverse Events and 6 more. Started Jun 2022; status: completed.
02
Drugs
tuvusertib
03
Conditions
solid tumortriple negative breast cancer (TNBC)Epithelial Ovarian Cancer (EOC)prostate cancer (PCa)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05396833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05396833.